Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.34 |
| ▸ | GUSB | P08236 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105484 | 0.84 | FYN (0.31) | — | |
| SCHEMBL21347098 | 0.76 | HSD11B1 (0.32) | — | |
| SCHEMBL21101827 | 0.76 | CYP1A2 (0.47) | CYP1A2LSSHTT | |
| SCHEMBL25934484 | 0.74 | ALDH1A1 (0.41) | CYP1A2LSSALDH1A1GBA1MEN1 | |
| SCHEMBL21347099 | 0.74 | MAPT (0.33) | GBA1 | |
| SCHEMBL11568158 | 0.70 | GBA1 (0.37) | GBA1 | |
| SCHEMBL2048536 | 0.70 | — | — | |
| SCHEMBL6749100 | 0.70 | CYP1A2 (0.59) | CYP1A2LSSALDH1A1MEN1HTT | |
| SCHEMBL997470 | 0.70 | CYP1A2 (0.59) | CYP1A2LSSALDH1A1MEN1HTT | |
| SCHEMBL6753110 | 0.70 | CYP1A2 (0.59) | CYP1A2LSSALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339542-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339542-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | CYP1A2 2051/4885LSS 1857/4885ALDH1A1 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.